Table 1.
Participants’ characteristics.
| UPN | Demographics | Clinical Features | Molecular Features | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Age (Y) |
Gender | Tumor Location | Size (cm) |
Histology | Treatment Protocol | Mutations Somatic | Germline |
CNAs | Subgroup | Methylation Subtype |
|
| 1 | 14 | M | 4th ventricle | 4 | C | PNET5 | — | — | ¾ | VIII |
| 9 | 10 | F | 4th ventricle | 3.5 × 3 × 4 | C | PNET5 | CTNNB1 | — | 6- | WNT |
| 13 | 7 | F | 4th ventricle | 4.5 × 4.5 × 4 | C | PNET5 | CTNNB1 | — | 6- | WNT |
| 15p | 5 | M | 4th ventricle | 4.5 × 4 × 4 | C | PNET5 | — | — | ¾ | V |
| 15 r/m | 6 | M | 4th ventricle, base of scull, spinal cord | NA/0.4–0.6/0.7 | C | MEMMAT | — | — | ¾ | III |
| 19p | 4 | F | LCH | 6 × 5 × 3.8 | C | PNET5 | — | — | SHH | A |
| 19r | 5 | F | LCH | 0.4/0.6/0.2 | C | TOTEM | — | — | SHH | A |
| 21 | 4 | M | 4th ventricle | 4.5 × 4 × 3.7 | C | HIT Medguidance | — | — | ¾ | VI |
| 22 | 5 | M | 4th ventricle | 4.5 × 5 × 4 | C | PNET5 | — | — | ¾ | VI * |
| 24 | 1 | F | RCH | 2.5 | D/N | HIT-SKK | — | — | SHH | B |
| 27 | 1 | M | Vermis | 4.5 × 3.5 × 4 | D/N | HIT-SKK | — | SUFU | — | SHH | B |
| 31 | 2 | F | 4th ventricle | 3.5 × 3 × 3.5 | N | HIT Medguidance | SMO, KMT2D | — | — | SHH | B |
| 35 | 5 | M | 4th ventricle | 2.4 | C | PNET5 | CTNNB1 | — | — | WNT |
| 43 | 15 | F | 4th ventricle | 4 × 3.5 × 2.5 | C | NA | KDM6A | — | — | ¾ | NA |
UPN, unique patient number; p, primary tumor; r, local relapse; m, metastasis; LCH, left cerebellar hemisphere; RCH, right cerebellar hemisphere; C, classical; D, desmoplastic; N, nodular; NA, data not available. Tumor location and size as denoted on diagnostic MRI. Clinical subgroup assigned according to the 2016 WHO Classification of Tumors of the CNS. Methylation subtype in capital letters/roman numerals based on methylation array data processed through DKFZ brain tumor methylation classifier with scores ≥ 0.9 (asterisk denotes a score 0.5–0.9).